Project Grant K43TW012585
- This Project Grant award of $781,129 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a 5-year study to validate and extend an integrated host-microbe (IHM) diagnostic approach for accurately diagnosing lower respiratory tract infections (LRTIs) in critically ill children. The study aims to: 1) validate the performance of the existing IHM LRTI diagnostic classifier, 2) develop a novel host gene expression...
- This National Institutes of Health (NIH) R21/R33 grant award in the amount of $734,360 aims to develop and validate an innovative, inexpensive multi-modal digital stethoscope capable of automated lung sound and respiratory rate analysis, with mobile phone interoperability to an electronic health (eHealth) platform for real-time lower respiratory infection (LRI) and antibiotic surveillance in low- and middle-income countries (LMICs). The grant, awarded under the NIH's Child Health and Human...
- This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $212,636 to Socios En Salud Sucursal Peru, a non-profit healthcare organization in Peru. The grant supports the development of tools to help primary care physicians in low- and middle-income countries better identify child and adolescent tuberculosis (TB) household contacts who require further...
- This $136,718 Project Grant award from the National Institutes of Health's Fogarty International Center (CFDA 93.989 - International Research and Research Training) supports a study to investigate the long-term respiratory health impacts of pulmonary tuberculosis in children and adolescents in The Gambia. The project, led by Principal Investigator Dr. Esin Nkereuwem from the Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, aims to: 1) characterize...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize metabolic profiles and outcomes among tuberculosis (TB) patients in Tanzania. The $201,549 award to the Medical University of South Carolina will fund a 5-year study with the following objectives: Measure and describe metabolic markers and TB severity at the time of TB diagnosis, testing...
- This is a Project Grant awarded by the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), for the development and implementation of a pediatric AI multi-modal digital stethoscope and respiratory surveillance system in South Africa. The $261,763 award aims to develop and validate an innovative, inexpensive multi-modal digital stethoscope capable of automated lung sound and respiratory rate...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), is supporting a $182,726 research initiative led by Dr. Sara Kim at Seattle Children's Hospital and the University of Washington. The project aims to understand the immune parameters associated with preventing Respiratory Syncytial Virus (RSV) lower respiratory tract infections in hematopoietic cell transplant recipients, a population at high...
- The Fogarty International Center (FIC), part of the U.S. Department of Health and Human Services' National Institutes of Health, has awarded a $169,015 Project Grant (CFDA 93.989) to Kenyatta National Hospital in Kenya. The goal of this 5-year grant, awarded on September 16, 2025, is to develop and evaluate a urine dipstick-guided counseling intervention to support adherence and completion of the 3-month isoniazid with rifapentine (3HP) tuberculosis preventive therapy regimen among people with...
- The federal Project Grant award of $244,044.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop an integrated diagnostic test that uses a single nasal swab sample to detect both pathogens and the host immune response in order to identify the cause of lower respiratory tract infections (LRTI). The award will enable the grantee, Duke University, to achieve the following specific aims over...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,136,143 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to study post-tuberculosis lung disease (PTLD) in youth with and without HIV globally. The project will leverage the Tuberculosis Sentinel Research Network (TB-SRN) in 11 countries to establish the prevalence of PTLD in youth, identify modifiable risk factors, and assess the impact on quality of life....
CLINICAL DECISION SUPPORT ALGORITHM TO OPTIMIZE MANAGEMENT OF RESPIRATORY TRACT INFECTION IN CHILDREN ATTENDING PRIMARY HEALTH FACILITIES IN KILIMANJARO REGION, TANZANIA - ABSTRACT IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS), RESPIRATORY TRACT INFECTIONS (RTIS) ARE A LEADING CAUSE OF PREVENTABLE DEATH AMONG YOUNG CHILDREN (< 5 YEARS OF AGE). SEVERE RTIS, USUALLY INVOLVING THE LOWER RESPIRATORY TRACT, CONSTITUTE A POTENTIALLY LIFE-THREATENING MEDICAL PROBLEM THAT REQUIRES EFFECTIVE DIAGNOSIS AND MANAGEMENT, INCLUDING EVALUATION FOR ANTIBACTERIALS. AT THE SAME TIME, THE VAST MAJORITY OF RTIS IN YOUNG CHILDREN ARE NON-SEVERE AND OFTEN CAUSED BY VIRUSES. FOR THESE EXCEEDINGLY COMMON, NON-SEVERE VIRAL RTI CASES, ANTIBACTERIALS ARE NOT APPROPRIATE AND COULD CAUSE HARM. YET IN LMICS OF AFRICA AND ASIA, RESEARCH STUDIES HAVE SHOWN THAT ANTIBACTERIALS ARE PRESCRIBED FOR OVER 75% OF OUTPATIENT PEDIATRIC RTI VISITS. RTI MANAGEMENT IS THUS HIGHLY PROBLEMATIC: ON THE ONE HAND, A COMMON SYNDROME THAT IS GROSSLY OVER-TREATED WITH INAPPROPRIATE ANTIBACTERIALS; ON THE OTHER HAND, CLINICIANS IN LOW-RESOURCED LMIC SETTINGS CAN UNDERSTANDABLY BE CONCERNED THAT WITHHOLDING ANTIBACTERIALS COULD RUN THE RISK OF A PEDIATRIC RTI PROGRESSING TO A SEVERE, LIFE-THREATENING CONDITION. THIS K43 APPLICATION PRESENTS A CAREER DEVELOPMENT PROGRAM TO 1) DEVELOP A CLINICAL PREDICTION RULE THAT USES A PARSIMONIOUS COMPOSITE OF CLINICAL COVARIATES AND NOVEL BIOMARKERS TO ACCURATELY DIFFERENTIATE VIRAL FROM BACTERIAL RTI AND TO PROVIDE PROGNOSTIC RISK STRATIFICATION OF DISEASE SEVERITY IN YOUNG CHILDREN PRESENTING TO HEALTH FACILITIES IN KILIMANJARO REGION, TANZANIA; 2) CONDUCT FORMATIVE SOCIAL SCIENCE RESEARCH TO UNDERSTAND CAREGIVER AND HEALTHCARE PROVIDER EXPECTATIONS, ATTITUDES AND ACCEPTABILITY THRESHOLDS FOR WITHHOLDING ANTIBACTERIALS IN UNCOMPLICATED VIRAL RTI; 3) USE HUMAN-CENTERED DESIGN METHODOLOGY TO PACKAGE THE PREDICTION RULE AND THE ATTITUDES, EXPECTATIONS AND NEEDS OF CAREGIVERS AND HEALTHCARE PROVIDERS INTO A USER-FRIENDLY, EFFECTIVE CLINICAL DECISION SUPPORT ALGORITHM THAT COULD BE TESTED IN FUTURE STUDIES FOR FEASIBILITY, SAFETY, AND EFFICACY. THE CANDIDATE FOR THIS CAREER DEVELOPMENT AWARD IS A TANZANIAN MEDICAL DOCTOR WITH ADVANCED TRAINING IN CLINICAL RESEARCH, PUBLIC HEALTH, AND EPIDEMIOLOGY. HE HAS CONDUCTED CLINICAL RESEARCH ON RTI IN TANZANIA SINCE 2016. FOR THIS MENTORED RESEARCH AWARD, THE CANDIDATE HAS ASSEMBLED AN EXCEPTIONAL TEAM OF MENTORS WITH EXPERTISE IN CLINICAL-EPIDEMIOLOGIC RESEARCH OF INFECTIOUS DISEASES IN TANZANIA, CLINICAL PREDICTION ANALYSIS, HUMAN-CENTERED INTERVENTION DESIGN IN TANZANIA AND OTHER LMICS, AS WELL AS A COLLABORATOR WITH EXPERTISE IN ALGORITHM DEVELOPMENT FOR INNOVATIVE APPROACHES TO RTI MANAGEMENT IN LMICS. AT THE CONCLUSION OF THIS AWARD, THE CANDIDATE WILL HAVE DEVELOPED UNIQUE EXPERTISE 1) IN CLINICAL PREDICTION FOR INFECTIOUS DISEASE MANAGEMENT IN SUB-SAHARAN AFRICA AND 2) IN HUMAN-CENTERED DESIGN OF CLINICAL DECISION SUPPORT ALGORITHMS. HE WILL EMERGE AS A GLOBAL LEADER IN INTERVENTION DESIGN FOR MANAGEMENT OF INFECTIOUS DISEASES-A HIGHLY-SKILLED INDEPENDENT INVESTIGATOR FOCUSED ON IMPLEMENTATION OF STRATEGIES THAT WILL CONFRONT EARLY CHILDHOOD MORTALITY AND THE GROWING THREAT OF ANTIMICROBIAL RESISTANCE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $28.6k | 9/19/25 | ||
| Not listed | $78.4k | 4/18/25 | ||
| Not listed | $78.4k | 4/18/25 | ||
| Not listed | $75.9k | 4/16/24 | ||
| Not listed | $75.9k | 4/16/24 |